Clinical Trials Browser

Insulin-Like Growth Factor I, Resistance To × Clear all

NCT06866548 2025-12-04

Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase EARLY_PHASE1 Active not recruiting

7 enrolled

Genitourinary

Insulin-Like Growth Factor I, Resistance To, Neoplasm Metastasis, Prostatic Neoplasms

NCT00889382 2024-11-20

A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)

Phase 1/2 Completed

152 enrolled

Gynecologic

Insulin-Like Growth Factor I, Resistance To, Ovarian Neoplasms

NCT00924989 2024-11-20

GALACCTIC

Phase 3 Completed

139 enrolled

Endocrine

Insulin-Like Growth Factor I, Resistance To, Adrenocortical Carcinoma

NCT00630552 2024-10-17

QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer

Phase 1/2 Completed

138 enrolled 19 charts

Gastrointestinal

Insulin-Like Growth Factor I, Resistance To, Pancreatic Neoplasms

NCT00807612 2024-09-25

QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

Phase 1/2 Terminated

15 enrolled 11 charts

Insulin-Like Growth Factor I, Resistance To

NCT04767750 2022-04-07

Role of LncRNA H19 in The Regulation of IGF-1R Expression

Completed

101 enrolled

Gastrointestinal

Insulin-Like Growth Factor I, Resistance To, Diabetes Mellitus, Type 2, Carcinoma, Hepatocellular, Neoplasms

NCT00684983 2020-03-24

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer

Phase 2 Completed

64 enrolled 13 charts

Breast

Insulin-Like Growth Factor I, Resistance To, Breast Neoplasms

NCT01733004 2016-08-04

A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors

Phase 1 Completed

42 enrolled

Gastrointestinal

Insulin-Like Growth Factor I, Resistance To, Carcinoma, Hepatocellular, Neoplasms

NCT00799240 2014-11-07

IMPACT

Phase 2 Completed

27 enrolled

Thoracic

Insulin-Like Growth Factor I, Resistance To, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pleural Effusion

NCT00956436 2013-09-16

Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)

Phase 1 Completed

40 enrolled

Gastrointestinal

Insulin-Like Growth Factor I, Resistance To, Carcinoma, Hepatocellular, Liver Neoplasms